Chimeric Therapeutics Ltd has released a press release.
Entitlement Offer to raise approximately $3.2 million
Filed with ASX ·
6ix hasn’t read this filing yet.
Chimeric Therapeutics Limited on 6ix
Earlier from Chimeric Therapeutics
- Reinstatement to Quotation
- Chimeric announces intention to undertake Entitlement Offer
- Suspension from Quotation
- Half Year Report and Appendix 4D 31 December 2024
- $4.0m Non-Dilutionary Funding
Later from Chimeric Therapeutics
- Prospectus
- Completion of Entitlement Offer
- ADVENT-AML Phase 1B clinical trial update
- $6.6 million Placement to advance clinical trial pipeline
- CHM CDH17 advances to dose level 2
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics